Alivus Life Sciences has announced its unaudited financial results for the third quarter and nine months ending December 31, 2025. The results, approved by the board on January 22, 2026, indicate a strong revenue from operations, totaling ₹6,728.89 Million for the quarter. The company continues to monitor developments related to the New Labour Codes for appropriate accounting adjustments.
Financial Performance Overview
Alivus Life Sciences reported its unaudited financial results for the third quarter (Q3) and nine months ending December 31, 2025. Key highlights from the report include:
- Revenue from Operations: ₹6,728.89 Million for the quarter ended December 31, 2025, compared to ₹5,879.80 Million for the quarter ended September 30, 2025 and ₹6,418.44 Million for the quarter ended December 31, 2024.
- Total Income: ₹6,868.17 Million for the quarter ended December 31, 2025.
Key Financial Metrics
The following table summarizes key financial figures (in ₹ Million):
| Particulars | 31 Dec 25 (Unaudited) | 30 Sep’25 (Unaudited) | 31 Dec’24 (Unaudited) | Nine Months ended 31 Dec 25 (Unaudited) | Nine Months ended 31 Dec 24 (Unaudited) | Year ended 31 Mar 25 (Audited) |
|---|---|---|---|---|---|---|
| Revenue from Operations | 6,728.89 | 5,879.80 | 6,418.44 | 18,627.15 | 17,373.39 | 23,868.84 |
| Total Income | 6,868.17 | 6,027.00 | 6,523.00 | 19,003.48 | 17,618.21 | 24,214.54 |
| Profit Before Tax | 1,983.92 | 1,741.37 | 1,851.47 | 5,355.10 | 4,628.41 | 6,541.31 |
| Profit for the Period | 1,502.61 | 1,300.26 | 1,369.60 | 4,018.22 | 3,437.59 | 4,856.27 |
Impact of New Labour Codes
The company is actively monitoring the impact of the new labour codes, which became effective November 21, 2025. An incremental impact was recognized, consisting of gratuity amounting to ₹170.02 million and compensated absences amounting to ₹86.55 million.
Equity and Earnings Per Share
The paid-up Equity Share Capital remains consistent at ₹245.36 Million. The Basic Earnings per share is ₹12.25 and Diluted Earnings per share is ₹12.22.
Source: BSE
